Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Abiraterone in mCRPC
NCT02043678Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2014
- Primary completion
- Feb 2018
- Modality
- Radiopharmaceutical
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Radium-223 + Abi/Pred with Placebo + Abi/Pred (2 arms). Primary endpoint: Symptomatic Skeletal Event Free Survival at 47 months. Started Mar 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02043678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043678.